243 related articles for article (PubMed ID: 8097964)
1. Biochemical consequences of resistance to tiazofurin in human myelogenous leukemic K562 cells.
Jayaram HN; Zhen W; Gharehbaghi K
Cancer Res; 1993 May; 53(10 Suppl):2344-8. PubMed ID: 8097964
[TBL] [Abstract][Full Text] [Related]
2. Relationships between the cytotoxicity of tiazofurin and its metabolism by cultured human lung cancer cells.
Carney DN; Ahluwalia GS; Jayaram HN; Cooney DA; Johns DG
J Clin Invest; 1985 Jan; 75(1):175-82. PubMed ID: 2856924
[TBL] [Abstract][Full Text] [Related]
3. Biochemical consequences of resistance to a recently discovered IMP dehydrogenase inhibitor, benzamide riboside, in human myelogenous leukemia K562 cells.
Jayaram HN; O'Connor A; Grant MR; Yang H; Grieco PA; Cooney DA
J Exp Ther Oncol; 1996 Sep; 1(5):278-85. PubMed ID: 9414415
[TBL] [Abstract][Full Text] [Related]
4. Mechanisms of resistance to 6-aminonicotinamide.
Saunders PP; Muhs MA; Arimilli S
Anticancer Res; 1996; 16(2):843-8. PubMed ID: 8687139
[TBL] [Abstract][Full Text] [Related]
5. Mechanism of resistance to tiazofurin in hepatoma 3924A.
Jayaram HN; Pillwein K; Lui MS; Faderan MA; Weber G
Biochem Pharmacol; 1986 Feb; 35(4):587-93. PubMed ID: 2868729
[TBL] [Abstract][Full Text] [Related]
6. Biochemical mechanisms of resistance to tiazofurin.
Jayaram HN
Adv Enzyme Regul; 1985; 24():67-89. PubMed ID: 3835825
[TBL] [Abstract][Full Text] [Related]
7. Tiazofurin: molecular and clinical action.
Weber G; Prajda N; Abonyi M; Look KY; Tricot G
Anticancer Res; 1996; 16(6A):3313-22. PubMed ID: 9042306
[TBL] [Abstract][Full Text] [Related]
8. Studies of purine and tiazofurin metabolism in drug sensitive human chronic myelogenous leukemia K 562 cells.
Pillwein K; Jayaram HN; Weber G
Blut; 1988 Aug; 57(2):97-100. PubMed ID: 3165681
[TBL] [Abstract][Full Text] [Related]
9. Studies on the mechanism of action of 2-beta-D-ribofuranosylthiazole-4-carboxamide--V. Factors governing the response of murine tumors to tiazofurin.
Ahluwalia GS; Jayaram HN; Plowman JP; Cooney DA; Johns DG
Biochem Pharmacol; 1984 Apr; 33(8):1195-203. PubMed ID: 6143562
[TBL] [Abstract][Full Text] [Related]
10. Biochemically directed therapy of leukemia with tiazofurin, a selective blocker of inosine 5'-phosphate dehydrogenase activity.
Tricot GJ; Jayaram HN; Lapis E; Natsumeda Y; Nichols CR; Kneebone P; Heerema N; Weber G; Hoffman R
Cancer Res; 1989 Jul; 49(13):3696-701. PubMed ID: 2567208
[TBL] [Abstract][Full Text] [Related]
11. Unique bioactivation of tiazofurin--studies with resistant cells.
Kuttan R
Indian J Biochem Biophys; 1989 Jun; 26(3):160-5. PubMed ID: 2620910
[TBL] [Abstract][Full Text] [Related]
12. Tiazofurin metabolism in human lymphoblastoid cells: evidence for phosphorylation by adenosine kinase and 5'-nucleotidase.
Fridland A; Connelly MC; Robbins TJ
Cancer Res; 1986 Feb; 46(2):532-7. PubMed ID: 3000575
[TBL] [Abstract][Full Text] [Related]
13. Comparison of biochemical parameters of benzamide riboside, a new inhibitor of IMP dehydrogenase, with tiazofurin and selenazofurin.
Gharehbaghi K; Sreenath A; Hao Z; Paull KD; Szekeres T; Cooney DA; Krohn K; Jayaram HN
Biochem Pharmacol; 1994 Oct; 48(7):1413-9. PubMed ID: 7945441
[TBL] [Abstract][Full Text] [Related]
14. Targets and markers of selective action of tiazofurin.
Weber G; Natsumeda Y; Pillwein K
Adv Enzyme Regul; 1985; 24():45-65. PubMed ID: 2424286
[TBL] [Abstract][Full Text] [Related]
15. Purine metabolism of human glioblastoma in vivo.
Pillwein K; Chiba P; Knoflach A; Czermak B; Schuchter K; Gersdorf E; Ausserer B; Murr C; Goebl R; Stockhammer G
Cancer Res; 1990 Mar; 50(5):1576-9. PubMed ID: 2154328
[TBL] [Abstract][Full Text] [Related]
16. Biochemically targeted therapy of refractory leukemia and myeloid blast crisis of chronic granulocytic leukemia with Tiazofurin, a selective blocker of inosine 5'-phosphate dehydrogenase activity.
Tricot G; Weber G
Anticancer Res; 1996; 16(6A):3341-7. PubMed ID: 9042309
[TBL] [Abstract][Full Text] [Related]
17. Nicotinamide mononucleotide adenylyltransferase2 overexpression enhances colorectal cancer cell-kill by Tiazofurin.
Kusumanchi P; Zhang Y; Jani MB; Jayaram NH; Khan RA; Tang Y; Antony AC; Jayaram HN
Cancer Gene Ther; 2013 Jul; 20(7):403-12. PubMed ID: 23764899
[TBL] [Abstract][Full Text] [Related]
18. Studies on the mechanism of action of tiazofurin (2-beta-D-ribofuranosylthiazole-4-carboxamide). VI. Biochemical and pharmacological studies on the degradation of thiazole-4-carboxamide adenine dinucleotide (TAD).
Ahluwalia GS; Cooney DA; Marquez VE; Jayaram HN; Johns DG
Biochem Pharmacol; 1986 Nov; 35(21):3783-90. PubMed ID: 2877671
[TBL] [Abstract][Full Text] [Related]
19. Effects of the IMP-dehydrogenase inhibitor, Tiazofurin, in bcr-abl positive acute myelogenous leukemia. Part II. In vitro studies.
Wright DG; Boosalis M; Malek K; Waraska K
Leuk Res; 2004 Nov; 28(11):1137-43. PubMed ID: 15380336
[TBL] [Abstract][Full Text] [Related]
20. 2-(3-Amino-3-deoxy-beta-D-xylofuranosyl)thiazole-4-carboxamide: a new tiazofurin analogue with potent antitumour activity.
Popsavin M; Spaić S; Svircev M; Kojić V; Bogdanović G; Popsavin V
Bioorg Med Chem Lett; 2006 Oct; 16(20):5317-20. PubMed ID: 16908146
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
